Malcolm Leissring reports on the latest data, presented at the 8th International Conference on Alzheimer’s Disease and Related Disorders in Stockholm, on the role of insulin-degrading enzyme and neprilysin in degrading Aβ peptide in vivo....
At the Society for Neuroscience meeting last November in San Diego, the Alzheimer Research Forum reported on insulin-degrading enzyme as a potential risk factor for late-onset Alzheimer's disease...
In tomorrow's Nature Medicine, Bruce Yankner at Children's Hospital in Boston offers up a partial explanation for one of the abiding questions in Parkinson's research: Why do neurons die in such a selective pattern?...
A report in next week's PNAS adds to the growing evidence that insulin-degrading enzyme (IDE), or insulysin, plays a role in the degradation of amyloid-β (Aβ)...
There may be no Shangri-La or fountain of eternal youth, but that does not stop scientists from searching for that biochemical reaction or signal transduction pathway that may hold the key to a longer and healthier "old age."
A flurry of recent papers is shedding new light on the role of proteins containing expanded polyglutamine tracts (polyQ) and their molecular partners, bringing researchers a small step closer toward understanding...
Insulin resistance is emerging as a possible risk factor for Alzheimer’s, and data from a pilot trial presented at the 2002 Neuroscience meeting indicate that an insulin-sensitizing drug may represent a novel treatment approach...
In this week's early online edition of PNAS, researchers report that chaperones may play a vital role in regulating protein aggregation in Alzheimer's disease (AD)...
Passive antibody immunization against prion protein prevents the spread of clinical disease to the brain of mice, even though the antibody works primarily by reducing prion replication in peripheral tissues, including the spleen. This is the astonishing news in a report in today’s Nature...
Keith Crucher reports from the World Alzheimer Congress: In the symposium on amyloid-lowering strategies, Dennis Dickson presented a unique and clever approach to addressing the likelihood that macrophage-mediated clearance of amyloid will be an effective strategy in humans....
The old dogma that the brain and the immune system don't mix is crumbling. We now know that the CNS is not entirely privileged, and that immune cells do invade it under certain conditions. This realization...
In an advanced online publication in this week's Nature Medicine, doctors report the first autopsy of a patient enrolled in trials for the ill-fated Alzheimer's disease (AD) vaccine...
Two papers in tomorrow's Science provide ong-awaited evidence for the notion that the two pathological hallmarks of Alzheimer's disease are interconnected. Using different approaches...
Despite its long and distinguished history in Alzheimer’s research, the microtubule-stabilizing protein tau still poses many a riddle to scientists. They do know that excessive phosphorylation of tau somehow figures in neurodegeneration...